NasdaqCM - Nasdaq Real Time Price USD

Journey Medical Corporation (DERM)

6.88
0.00
(0.00%)
At close: May 9 at 4:00:00 PM EDT
7.09
+0.21
+(3.05%)
After hours: May 9 at 4:54:04 PM EDT
Loading Chart for DERM
  • Previous Close 6.88
  • Open 6.92
  • Bid 6.70 x 100
  • Ask 7.07 x 100
  • Day's Range 6.81 - 7.04
  • 52 Week Range 3.20 - 7.84
  • Volume 96,365
  • Avg. Volume 76,267
  • Market Cap (intraday) 159.072M
  • Beta (5Y Monthly) 0.87
  • PE Ratio (TTM) --
  • EPS (TTM) -0.72
  • Earnings Date May 14, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 9.88

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Emrosi for the treatment of inflammatory lesions of rosacea, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.

journeymedicalcorp.com

41

Full Time Employees

December 31

Fiscal Year Ends

Recent News: DERM

View More

Performance Overview: DERM

Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

DERM
75.96%
S&P 500 (^GSPC)
3.77%

1-Year Return

DERM
94.90%
S&P 500 (^GSPC)
8.55%

3-Year Return

DERM
83.96%
S&P 500 (^GSPC)
41.81%

5-Year Return

DERM
20.92%
S&P 500 (^GSPC)
93.18%

Compare To: DERM

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: DERM

View More

Valuation Measures

Annual
As of 5/9/2025
  • Market Cap

    159.07M

  • Enterprise Value

    163.85M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.50

  • Price/Book (mrq)

    7.93

  • Enterprise Value/Revenue

    2.92

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -26.14%

  • Return on Assets (ttm)

    -10.88%

  • Return on Equity (ttm)

    -72.60%

  • Revenue (ttm)

    56.13M

  • Net Income Avi to Common (ttm)

    -14.67M

  • Diluted EPS (ttm)

    -0.72

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    20.3M

  • Total Debt/Equity (mrq)

    128.08%

  • Levered Free Cash Flow (ttm)

    -18.57M

Research Analysis: DERM

View More

Company Insights: DERM

Research Reports: DERM

View More

People Also Watch